1. Introduction {#sec1}
===============

Maintaining an optimal level of comfort and safety for critically ill patients is a universal goal in postoperative care \[[@B1], [@B2]\]. This can be achieved with the use of alpha-2 adrenergic agents, in particular, clonidine and dexmedetomidine, which induce dose-dependent sedation, analgesia, and anxiolysis \[[@B3], [@B4]\]. Clonidine has traditionally been used in our institution for sedation in the perioperative setting and in critically ill patients after cardiac surgery \[[@B5]--[@B9]\]. Particular benefits of this sedative are its low acquisition costs. Adverse effects of clonidine are hypotension and bradycardia \[[@B10]\], which might limit its use in haemodynamic unstable patients.

In 2013, dexmedetomidine was introduced into the Swiss market. The number of reports describing the benefits of dexmedetomidine is growing continuously since then: dexmedetomidine reduced the lengths of mechanical ventilation and hospital stay, and it lowered the overall costs compared with that of propofol \[[@B11]--[@B13]\]. The perioperative use of dexmedetomidine was associated with a decreased incidence of postoperative complications, delirium, and mortality up to one year after cardiac surgery \[[@B14]\]. However, dexmedetomidine treatment is expensive and might not be universally available.

To date, there is a shortage of studies comparing dexmedetomidine and clonidine in the intensive care unit (ICU) setting. The only direct comparison between the two alpha-2 agonists available is limited by the low number of included patients (*n* = 35 per group) \[[@B15]\].

2. Materials and Methods {#sec2}
========================

2.1. Objectives {#sec2.1}
---------------

The aim of this study was to assess the haemodynamic adverse effects of the alpha-2 agonists clonidine and dexmedetomidine in critically ill patients after cardiac surgery.

2.2. Design {#sec2.2}
-----------

The study is a retrospective observational study. The study protocol was approved by the ethics council of the Canton of Zurich, Switzerland (BASEC-Nr. PB_2016-00333). Patients\' general consent was required for the screening of their charts and the retrospective analysis of their data.

2.3. Setting {#sec2.3}
------------

The study was performed in the cardiosurgical ICU at the University Hospital Zurich, Switzerland. The treatment principles of patients hospitalized in this particular ICU have been summarized \[[@B16], [@B17]\]. In our practice, patients generally arrive from the operation room under propofol sedation. Alpha-2 agonists are second-line agents when prolonged sedation becomes necessary. In our clinical practice, clonidine is used in haemodynamically stable patients with norepinephrine requirements \<0.1 mcg/kg/min, while dexmedetomidine is used in patients with a norepinephrine requirement \<0.3 mcg/kg/min. The patients requiring higher norepinephrine support are usually sedated with midazolam. However, no strict sedation guidelines were applied during the study period, and the choice of sedative was at the discretion of the ICU consultant on call.

2.4. Data Collection {#sec2.4}
--------------------

Demographic and baseline characteristics including the Simplified Acute Physiology Score (SAPS) II were collected for both groups. Higher SAPS values indicate more severe illness and a higher predicted mortality \[[@B18]\]. Medical information and laboratory data were extracted from the electronic patient information system. Medication and haemodynamic variables were collected from the handwritten patients\' charts.

2.5. Population {#sec2.5}
---------------

All patients admitted to our cardiovascular ICU during an 18-month-period were screened for treatment with either clonidine (Catapresan®) and/or dexmedetomidine (Dexdor®). Study inclusion criteria for patients were treatment with either clonidine or dexmedetomidine. The exclusion criteria were absence of consent for screening, treatment with both clonidine and dexmedetomidine during the same ICU stay, only drug bolus administration in absence of a continuous drug infusion, absence of cardiac surgery, use of either extracorporeal life support, or ventricular assist devices. Patients were included in the analysis only once. Those receiving both clonidine and dexmedetomidine during the same ICU stay were not considered for this comparison.

2.6. Variables {#sec2.6}
--------------

Heart rate, mean arterial pressure, and norepinephrine requirements were recorded 3-hourly. The observation period started with the beginning of the alpha-2 agonist infusion and ended 12-hours later. Bradycardia was defined as a decrease of the heart rate below 60 beats per minute.

2.7. Study Size {#sec2.7}
---------------

The study size was defined by the 30-month screening period (convenience sample).

2.8. Statistics {#sec2.8}
---------------

Median (interquartile range) and numbers (percentages) were calculated for the overall sample and subgroups. Missing values were replaced by the last recorded value (carrying forward). Comparisons were made with the use of the Mann--Whitney *U* test, Fisher\'s exact test, or the chi-squared test, as appropriate. The null hypothesis was rejected with a two-sided *p* value \< 0.05. All analyses were performed with the use of SPSS 24 for Windows 10.

3. Results {#sec3}
==========

During the 30-month study period, 2769 patients were admitted to the cardiosurgical ICU. A summary of included and excluded patients is given in [Figure 1](#fig1){ref-type="fig"}. Eventually, this study compared 193 patients sedated with clonidine and 141 patients sedated with dexmedetomidine. Patient characteristics are displayed in [Table 1](#tab1){ref-type="table"}.

All patients underwent cardiac surgery, which included valve surgery in 179 (54%), coronary artery bypass surgery in 137 (41%), aortic dissection surgery in 35 (10.5%), aortic aneurysm surgery in 50 (15%), other major vascular surgery in 25 (7.5%), myocardial resection in 5 (1.5%), implantable cardioverter defibrillator implantation in 12 (3.6%), and heart transplantation in 9 (2.7%) patients. Several patients received combinations of the above-listed interventions. Cardiopulmonary bypass was required in 251 (75%) of the operations without significant difference between the two patient groups (*p*=0.31). The postoperative left ventricular ejection fraction in both groups was 55 (45--60)%; *p*=0.16.

The average initial dose of clonidine was 0.38 (0.29--0.50) mcg/kg/h. The average initial dexmedetomidine dose was 0.80 (0.61--1.12) mcg/kg/h. Both drugs were started on ICU day 2 (1--3); *p*=0.18. Patients were treated with clonidine for a total duration of 16 (11--50) hours. In the dexmedetomidine group, patients received the drug infusion for a total duration of 31 (13--68) hours. Study drug doses over time are displayed in [Figure 2](#fig2){ref-type="fig"}.

Haemodynamic variables, laboratory values, and ICU management at the start of clonidine or dexmedetomidine treatment are shown in [Table 2](#tab2){ref-type="table"}. As shown in [Figure 3(a)](#fig3){ref-type="fig"}, the median arterial pressure remained stable in both groups during the twelve-hour observation period. Heart rate decreased in both groups by −10 (−20--0) bpm (*p*=0.33), [Figure 3(b)](#fig3){ref-type="fig"}. Bradycardia developed in 7.8% of the patients treated with clonidine and 5.7% of patients treated with dexmedetomidine (*p*=0.52). At the beginning of the alpa-2 agonist infusion, norepinephrine requirements were higher in patients receiving dexmedetomidine (0.05 (0.00--0.11) vs 0.12 (0.03--0.19) mcg/kg/min, *p* \< 0.001). Between baseline and the twelve-hour follow-up, the norepinephrine requirements remained stable in the clonidine group (0.00 (−0.04--0.02) mcg/kg/min), whereas a decrease of norepinephrine was seen in the dexmedetomidine group (−0.03 (−0.10--0.02) mcg/kg/min, *p*=0.007) ([Figure 3(c)](#fig3){ref-type="fig"}. During the 12-hour observation period, a transient increase in norepinephrine was recorded in 95 (49%) patients treated with clonidine and 60 (43%) patients treated with dexmedetomidine (*p*=0.27) by 0.04 (0.03--0.08) and 0.06 (0.03--0.12) mcg/kg/min (*p*=0.014), respectively.

4. Discussion {#sec4}
=============

This retrospective analysis demonstrates that both clonidine and dexmedetomidine can be used safely for sedation of patients after cardiac surgery hospitalized in the ICU.

4.1. Population {#sec4.1}
---------------

Patients receiving dexmedetomidine were older and had a higher SAPS II score and a higher requirement for norepinephrine at the start of the drug infusion, indicating that these patients had a higher severity of illness than the patients treated with clonidine. This reflects our clinical practice that clonidine is used in haemodynamically more stable patients. This translated in a longer ICU length of stay in the dexmedetomidine group, while mortality was low in both groups.

4.2. Clonidine {#sec4.2}
--------------

We used clonidine in a median dose of 0.4 mcg/kg/h, while Srivastava et al. used a mean dosage of 1.4 mcg/kg/h. Haemodynamic instability is one of the most frequently mentioned side-effects of clonidine \[[@B10]\]. Srivastava et al. described the frequencies for bradycardia (heart rate below 50 bpm) and hypotension (systolic blood pressure below 80 mmHg or diastolic blood pressure below 50 mmHg) during clonidine infusion with 8.6% (3/35) and 31% (11/35), respectively \[[@B15]\]. In our ICU setting, the overall risk of bradycardia was below ten percent and mean arterial blood pressure remained stable due to adjustments of the norepinephrine doses. Overall, norepinephrine requirements did not increase during the 12-hour observation period.

The major advantages of clonidine are its low costs. A 24-hour treatment of an average study patient (body weight 79 kg, clonidine dose 0.4 mcg/kg/h) costs about 18 Euros. Based on our findings, we can recommend clonidine for sedation in ICU patients after cardiac surgery with norepinephrine requirements up to 0.1 mcg/kg/min at the beginning of the clonidine infusion, provided the patients are adequately monitored and managed.

4.3. Dexmedetomidine {#sec4.3}
--------------------

In the dexmedetomidine group, patients were treated with a median dose of 0.8 mcg/kg/h, while Srivastava et al. used a mean dose of only 0.4 mcg/kg/h. In the Midex and Prodex studies, the median dose of dexmedetomidine was 0.45 and 0.96 mcg/kg/h, respectively \[[@B19]\]. Hypotension (no definition provided) occurred in 21% (51/247) in the Midex study and in 13% (32/246) in the Prodex study \[[@B19]\]. Srivastava et al. described the frequencies for bradycardia (heart rate below 50 bpm) and hypotension (systolic blood pressure below 80 mmHg or diastolic blood pressure below 50 mmHg) during dexmedetomidine infusion with 11% (4/35) and 8.6% (3/35), respectively \[[@B15]\]. In our study, mean arterial blood pressure in the dexmedetomidine group remained stable over time. Less than half of the patients being treated with dexmedetomidine showed a transient increase of norepinephrine, while the overall norepinephrine need was decreasing during the observation period. This suggests that dexmedetomidine provides good haemodynamic stability.

In the Midex and Prodex studies, the risk of bradycardia (no definition provided) was 14.2% (35/247) and 13.0% (32/246), respectively \[[@B19]\]. In our study, the incidence of bradycardia was 5.7% in the dexmedetomidine group.

Up to now, merely one existing study directly compared the two alpha-2 agonists in the ICU setting. Srivastava\'s findings concerning the haemodynamic stability conform to our findings, namely, that dexmedetomidine showed a better haemodynamic stability than clonidine. However, due to distinctive drug dosages, it is not possible to make a proper comparison between the two studies: While we used twice as much dexmedetomidine, our clonidine infusion doses were lower by a factor of three. Additionally, Srivastava\'s study is limited by the small study group of 70 patients \[[@B15]\]. Recently, Morelli et al. investigated the effect of dexmedetomidine sedation on norepinephrine requirements in 38 septic shock patients in a crossover trial. Four hours after the stop of propofol and the initiation of a dexmedetomidine infusion of 0.7 ± 0.2 mcg/kg/h, the norepinephrine dose decreased from 0.69 ± 0.72 mcg/kg/min to 0.30 ± 0.25 *μ*·g/kg/min (*p* \< 0.005). Back on propofol 8 hours after stopping dexmedetomidine, norepinephrine increased again to 0.42 ± 0.36 *μ*g/kg/min (*p* \< 0.005) \[[@B20]\]. While the study population was different and the norepinephrine doses at baseline were much higher, the dexmedetomidine doses administered and the trend of the norepinephrine changes were similar, supporting in part the findings of the present study.

The costs for a 24-hour treatment of dexmedetomidine for an average study patient (body weight 78 kg, dexmedetomidine dose 0.8 mcg/kg/h) are approximately 224 Euros. Hence, dexmedetomidine therapy is exceeding the costs of clonidine by more than ten times. While clonidine is a good choice for haemodynamically stable patients (NA ≤ 0.1 mcg/kg/min), our study results suggest that dexmedetomidine is a safe option for patients with a moderate haemodynamic instability (norepinephrine \> 0.1, but ≤ 0.2 mcg/kg/min). For highly unstable patients (norepinephrine \> 0.2 mcg/kg/min), a treatment with another sedative (e.g., midazolam) may be considered.

Based on these data, prospective studies can be planned for a direct comparison between the two alpha-2 agonists, potentially also in patients with haemodynamic instability. More data regarding antidelirogenic effects and impact on length of mechanical ventilation or length of stay are needed for clonidine or dexmedetomidine treatments. As treatment with clonidine is inexpensive compared with dexmedetomidine, further research would be of economic interest for hospital administrators and public health.

4.4. Limitations {#sec4.4}
----------------

Our study has some important limitations. First, this study has a retrospective design, and the patients were not randomly allocated to a patient group. As a result, the two patient groups have different baseline characteristics, making a direct head-to-head comparison of the two drugs impossible. However, this study represents a real-life experience giving information on clinical practice in our institution.

Second, all study variables were assessed 3-hourly and reflect more the overall trend than short-term fluctuations. Hence, if the patients showed relevant changes between the assessment times, we might have missed those. Clearly, not every variable of the patient condition (e.g., altertness and pain) and ICU interventions (e.g., fluid administration, analgesics, and termination of propofol) that may affect blood pressure and heart rate was collected and analysed in this study. In addition, some patients in our ICU had transient epicardial pacemakers with the possibility of pacing for haemodynamic reasons. This may have had an impact on the incidence of bradycardia in our study. Nevertheless, our results reflect haemodynamic changes in critically ill patients after cardiac surgery treated with alpha-2 agonists under every day conditions.

5. Conclusions {#sec5}
==============

In patients treated with clonidine or dexmedetomidine, the incidence of bradycardia was below 10% and not different between groups. With clonidine, half of the patients required a mild increase in norepinephrine, while the overall norepinephrine use remained constant over 12 hours. With dexmedetomidine, less than half of the patients required a norepinephrine increase, while the overall norepinephrine use decreased during the observation period. This suggests that both dexmedetomidine and the lower-cost drug clonidine can be used safely for sedation in selected patients after cardiac surgery.
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Data Availability
=================

The data used to support this study are available from the corresponding author upon request.

Additional Points
=================

To date, there is a shortage of studies comparing the cardiovascular safety of dexmedetomidine and clonidine in the intensive care unit setting. This retrospective study assesses the hemodynamic adverse effects of clonidine and dexmedetomidine in critically ill patients after cardiac surgery. Between baseline and 12 hours, norepinephrine requirements remained stable in the clonidine group and decreased in the dexmedetomidine group. Bradycardia (HR \< 60 bpm) developed in less than 10% of patients with no difference between groups. Dexmedetomidine and the low-cost drug clonidine can both be used safely in selected patients after cardiac surgery.
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![Study population with inclusion and exclusion criteria. ECMO: extracorporeal membrane oxygenation; VAD: ventricular assist device; ICU: intensive care unit.](CCRP2020-4750615.001){#fig1}

![Drug dosages during dexmedetomidine and clonidine infusion. The clonidine and dexmedetomidine doses decreased by −0.14 (−0.35--0.00) mcg/kg/h and −0.12 (−0.69--0.21), respectively. Values indicate median ± interquartile range. Solid line (──) indicates clonidine patients; dashed line (- - -) indicates dexmedetomidine patients. Values represent median (interquartile range).](CCRP2020-4750615.002){#fig2}

![Hemodynamic variables during dexmedetomidine and clonidine infusion. Solid line (──) indicates clonidine patients; dashed line (- - -) indicates dexmedetomidine patients. Values represent median (interquartile range).](CCRP2020-4750615.003){#fig3}

###### 

Patient characteristics.

  Variable                    All (*n* = 334)   Clonidine group (*n* = 193)   Dexmedetomidine group (*n* = 141)   *p* value
  --------------------------- ----------------- ----------------------------- ----------------------------------- -----------
  Age (years)                 68 (58--75)       66 (57--73)                   70 (63--77)                         **0.003**
  Male gender                 256 (77%)         145 (75%)                     111 (79%)                           0.513
  Weight (kg)                 78 (68--90)       79 (69--91)                   78 (68--88)                         0.188
  SAPS II (points)            37 (29--50)       35 (27--48)                   41 (31--54)                         **0.008**
  ICU length of stay (days)   5 (2--8)          4 (2--7)                      6 (3--8)                            **0.004**
  ICU mortality               12 (3.6%)         7 (3.6%)                      5 (3.5%)                            1.000

ICU: intensive care unit; SAPS: simplified acute physiology score.

###### 

Physiological, laboratory, and treatment variables at the start of clonidine or dexmedetomidine therapy.

  Variable                                   All (*n* = 334)               Clonidine group (*n* = 193)   Dexmedetomidine group (*n* = 141)   *p* value
  ------------------------------------------ ----------------------------- ----------------------------- ----------------------------------- -----------
  Hemodynamic parameters                                                                                                                      
  \(i\) Heart rate (1/min)                   90 (80--100)                  90 (75--100)                  90 (80--105)                        **0.028**
  \(ii\) Mean arterial pressure (mmHg)       70 (65--75) *n* = 333         70 (65--80) *n* = 192         70 (65--75)                         0.093
  \(iii\) Central venous pressure (mmHg)     10 (7--12) *n* = 322          9 (6--12) *n* = 185           10 (8--13) *n* = 137                **0.025**
  \(iv\) Cardiac index (l/m \[[@B2]\]/min)   2.7 (2.5--3.3) *n* = 51       2.6 (2.4--3.0) *n* = 19       2.8 (2.6--3.5) *n* = 32             0.101
  \(v\) SvO~2~ (%)                           69 (63--75) *n* = 239         69 (64--75) *n* = 173         65 (59--75) *n* = 66                0.060
                                                                                                                                             
  Laboratory values                                                                                                                           
  \(i\) Haemoglobin (g/l)                    91 (83--103) *n* = 331        94 (85--107)                  88 (80--97) *n* = 138               **0.002**
  \(ii\) White blood cell count (G/l)        11.5 (8.8--15.1) *n* = 331    11.8 (8.8--15.1) *n* = 191    11.1 (8.6--15.1) *n* = 140          0.498
  \(iii\) C-reactive protein (mg/l)          62 (14--131) *n* = 326        53 (6--133) *n* = 185         69 (34--129)                        0.100
  \(iv\) Procalcitonin (mcg/l)               1.91 (0.52--6.25) *n* = 46    1.43 (0.31--4.10) *n* = 28    3.46 (1.10--17.07) *n* = 18         0.075
  \(v\) Creatinine (mcmol/l)                 99 (78--141)                  94 (76--133)                  110 (83--150)                       **0.005**
  \(vi\) Aspartate transaminase (U/l)        62 (39--119) *n* = 322        55 (35--107) *n* = 184        71 (44--133) *n* = 138              **0.026**
  \(vii\) Alanine transaminase (U/l)         27 (17--58) *n* = 325         27 (16--58) *n* = 188         28 (17--63) *n* = 137               0.606
  \(viii\) Creatine kinase (U/l)             474 (242--847) *n* = 329      484 (228--889) *n* = 188      468 (255--807) *n* = 141            0.919
  \(ix\) Myoglobin (mcg/l)                   371 (218--767) *n* = 325      378 (229--670) *n* = 186      368 (214--898) *n* = 139            0.640
  \(x\) Troponin (mcg/l)                     0.81 (0.35--1.69) *n* = 320   0.78 (0.30--1.54) *n* = 184   0.84 (0.43--1.97) *n* = 136         0.135
  \(xi\) Arterial lactate (mmol/l)           1.5 (1.0--2.3) *n* = 330      1.4 (1.05--2.2)               1.5 (1.0--2.6) *n* = 137            0.650
  \(xii\) Arterial base excess (mmol/l)      −1.1 (−3.0--0.3) *n* = 330    −1.2 (−2.7--0.3)              −1.0 (−3.3--0.4) *n* = 137          0.574
                                                                                                                                             
  Treatments                                                                                                                                  
  Propofol *n* (%)                           127 (38%)                     70 (36%)                      57 (40%)                            0.494
                                                                                                                                             
  Mechanical ventilation                                                                                                                      
  \(i\) Invasive *n* (%)                     235 (70%)                     124 (64%)                     111 (79%)                           **0.017**
  \(ii\) Noninvasive *n* (%)                 7 (2.1 %)                     5 (2.6%)                      2 (1.4%)                             
  Renal replacement therapy-*n* (%)          34 (10.2 %)                   23 (12%)                      11 (7.8%)                           0.235
  Norepinephrine *n* (%)                     248 (74 %)                    133 (69 %)                    115 (82%)                           **0.011**
                                                                                                                                             
  Inotropes                                                                                                                                   
  \(i\) Milrinone *n* (%)                    80 (24%)                      35 (18%)                      45 (32%)                            **0.004**
  \(ii\) Epinephrine *n* (%)                 73 (22%)                      33 (17%)                      40 (28%)                            **0.016**

SvO~2~: central venous oxygen saturation. Variables were collected at start of clonidine or dexmedetomidine treatment.
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